SARS-CoV-2 suppresses innate immunity

SARS-CoV-2, the virus that causes COVID-19, inhibits tissue-activating immune processes that normally lead to the production and / or signaling of type I interferon (IFN-I) by the cell and the infectious cigarettes. IFN-I is a key component of host native immunity responsible for the early eradication of the virus, as summarized in a recent review article in Journal of Interferon & Cytokine Research (JICR). By destroying the immune system, the virus reproduces and spreads in the body undetected, leading to a disease called COVID-19.

SARS-CoV-2 uses a variety of approaches to suppress IFN-I host response, including elimination of IFN-I production and IFN-I signaling. Viruses that are deficient in response to IFN-I response, in combination with replica mutations, may be developed as impaired live vaccine candidates. “

Hongjie Xia and Pei-Yong Shi, Medical Branch of the University of Texas at Galveston

“Focusing on indigenous immunity is particularly attractive for therapeutic and immunization strategies aimed at controlling SARS-CoV-2 infection and protecting against COVID-19. as the virus blocks tissue immune programs we can then build ways to restore these processes and strengthen anti-virus protection, “he said. Journal of Interferon & Cytokine Research Managing Editor Michael Gale Jr., Department of Psychology and Center for Internal and Immune Disease, University of Washington.

Other COVID related articles in this issue of Journal of Interferon & Cytokine Research introduce a review by Benjamin Liu and Harry Hill of the role of immune and inflammatory responses in COVID-19 cases with primary immunodeficiency. Patients with primary immunodeficiency are at high risk from viral infections including SARS-CoV-2. The authors conclude that conventional intravenous immunoglobulin therapy may have some protective effects in patients with primary immunodeficiency.

Ricardo Pereda and coauthors will study the therapeutic efficacy of interferon alpha 2b treatment for overcoming COVID-19 patients. They showed that interferon treatment reduces the likelihood of staying in intensive care and increases patient survival after major or critical illness.